Historical Approval of DDAVP for Nocturnal Enuresis in Children
The evidence does not provide a specific year when DDAVP was first approved or recommended for nocturnal enuresis in children, but research studies document its use beginning in the 1970s 1, 2.
Timeline Based on Available Evidence
Early clinical use began in the 1970s:
- The earliest research study in the provided evidence dates to 1978, when desmopressin was already being investigated in a double-blind study for nocturnal enuresis in children 1
- A 1993 review article states that "desmopressin is a potent antidiuretic for nocturnal enuresis" and notes that "from 1974 to June 1992 only 21 patients using desmopressin had serious adverse reactions" 2, suggesting clinical use dating back to at least 1974
Formal guideline recognition:
- By 2004, the American Academy of Child and Adolescent Psychiatry formally recognized DDAVP as having "proven efficacy in the treatment of enuresis" in their practice parameters 3
- The 2010 International Children's Continence Society guidelines describe desmopressin as "evidence-based therapy (grade Ia evidence)" 4
Current FDA-Approved Indications
The FDA drug label confirms that DDAVP Tablets have been safely used in pediatric patients age 6 years and older with primary nocturnal enuresis for up to 6 months 5. The label does not specify the original approval year for this indication.
Key Historical Context
- Desmopressin (DDAVP) was synthesized in 1967 as a modification of arginine vasopressin (AVP) 2
- Clinical experience with desmopressin for enuresis spans approximately 50 years based on a 2022 review 6
- The intranasal formulation was developed first, followed later by oral tablet formulations 3
Based on the available evidence, DDAVP was first used clinically for nocturnal enuresis in children around 1974-1978, though the exact regulatory approval year is not documented in the provided sources.